Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
Crossref DOI link: https://doi.org/10.1007/s13555-022-00809-8
Published Online: 2022-10-21
Published Print: 2022-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pettitt, Dan
Plotnick, Michael
Gagne, Joshua
Funding for this research was provided by:
Janssen Pharmaceutica
Johnson and Johnson
Text and Data Mining valid from 2022-10-21
Version of Record valid from 2022-10-21
Article History
Received: 19 April 2022
Accepted: 5 September 2022
First Online: 21 October 2022